Thus, we have identified a new mechanism that may drive the morbidity of mutp53-expressing tumours and highlight an intercellular communication pathway consisting of a number of measurable well-characterised components (including Rab35, PODXL, RCP, DGKα, collagen organisation) which are amenable to pharmacological intervention and may constitute viable biomarkers to indicate the presence of metastatic tumours. The gene discussed is DGKA; the disease is neoplasm.